This inventor holds 3 USPTO granted patents, plus 1 CIPO patent. Top assignee: Kyowa Hakko Kirin Co., Limited. Active years: 2013-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013-2019
Title: The Innovations of Takashi Kayashita
Introduction
Takashi Kayashita is a notable inventor based in Sunto-gun, Japan. He has made significant contributions to the field of antibody stabilization, holding a total of 3 patents. His work focuses on improving the stability and efficacy of antibody preparations, which are crucial in various medical applications.
Latest Patents
One of Takashi Kayashita's latest patents is a method of stabilizing antibodies and creating stabilized solution-type antibody preparations. This invention provides a method for suppressing the formation of soluble associations of antibodies in a solution. It also addresses the prevention of chemically degraded products of antibodies, ensuring their stability in solution. The patent includes the development of solution-type antibody preparations that suppress the formation of soluble associations, chemically degraded products, and insoluble aggregates. Additionally, it introduces agents for stabilizing antibodies and preventing degradation.
Career Highlights
Takashi Kayashita is currently associated with Kyowa Hakko Kirin Co., Limited, a company known for its advancements in biopharmaceuticals. His work has been instrumental in enhancing the quality and reliability of antibody-based therapies.
Collaborations
He has collaborated with notable colleagues such as Yuji Ueno and Atsushi Ishihara, contributing to the innovative research and development in the field of antibody stabilization.
Conclusion
Takashi Kayashita's contributions to the field of antibody stabilization are significant and impactful. His patents reflect a commitment to improving medical treatments through innovative solutions. His work continues to influence the biopharmaceutical industry positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
